| Page 15 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.
  1. Home

Clinical Outcomes and Healthcare Resource Utilization for Patients With Lower-Risk Myelodysplastic Syndromes Treated With Erythropoiesis-Stimulating Agents

Author(s): 
Garcia-Manero G, Matsuno RK, McBride A, Mohammed H, Idryo D, Broome R, Herriman A, Johnson T, Wilkinson K, Schrag A, Johanson C, Izano M, Makinde A, Mukherjee S
Primary Author: 
Garcia-Manero G
Journal Title: 
Clinical Lymphoma, Myeloma & Leukemia
Original Publication Date: 
Sep 2024

Introduction: Real-world studies of lower-risk

Bone Marrow Disease(s): 

Myelodysplastic Syndromes Treatment (PDQ®): Health Professional Version

Author(s): 
PDQ Adult Treatment Editorial Board
Primary Author: 
PDQ Adult Treatment Editorial Board
Journal Title: 
PDQ Cancer Information Summaries
Original Publication Date: 
Sep 2024

This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of

Bone Marrow Disease(s): 

Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial

Author(s): 
Della Porta MG, Garcia-Manero G, Santini V, Zeidan AM, Komrokji RS, Shortt J, Valcárcel D, Jonasova A, Dimicoli-Salazar S, Tiong IS, Lin CC, Li J, Zhang J, Pilot R, Kreitz S, Pozharskaya V, Keeperman KL, Rose S, Prebet T, Lai Y, Degulys A, Paolini S,
Primary Author: 
Della Porta MG
Journal Title: 
The Lancet Haematology
Original Publication Date: 
Sep 2024

Background: The preplanned interim analysis of the COMMANDS trial showed greater efficacy of luspatercept than epoetin alfa for treating anaemia in erythropoiesis-stimulating agent (ESA)-naive patients with transfusion-dependent, lower-risk

Bone Marrow Disease(s): 

Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes

Author(s): 
Sirenko M, Bernard E, Creignou M, Domenico D, Farina A, Arango Ossa JE, Kosmider O, Hasserjian R, Jädersten M, Germing U, Sanz G, van de Loosdrecht AA, Gurnari C, Follo MY, Thol F, Zamora L, Pinheiro RF, Pellagatti A, Elias HK, Haase D, Sander B, Orna E,
Primary Author: 
Sirenko M
Journal Title: 
Blood
Original Publication Date: 
Sep 2024

Mutations in UBA1, which are disease-defining for VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome, have been reported in patients diagnosed with

Bone Marrow Disease(s): 

Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition

Author(s): 
Röth A, He G, Tong H, Lin Z, Wang X, Chai-Adisaksopha C, Lee JH, Brodsky A, Hantaweepant C, Dumagay TE, Demichelis-Gómez R, Rojnuckarin P, Sun J, Höglund M, Jang JH, Gaya A, Silva F, Obara N, Kelly RJ, Beveridge L, Buatois S, Chebon S, Gentile B,
Primary Author: 
Röth A
Journal Title: 
American Journal of Hematology
Original Publication Date: 
Sep 2024

Crovalimab is a novel C5 complement inhibitor that enables rapid and sustained C5 inhibition with subcutaneous, low-volume self-administration every 4 weeks.

Bone Marrow Disease(s):